NCT04810611 is a Phase 1 clinical trial of MBG453 in Myelodysplastic Syndromes, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT04810611?

NCT04810611 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT04810611?

Interventions in NCT04810611: MBG453, NIS793, canakinumab.

What condition does NCT04810611 study?

NCT04810611 studies Myelodysplastic Syndromes.

Is NCT04810611 still recruiting?

NCT04810611 is currently terminated. Last updated 10 October 2025.

Last reviewed 2025-10-10 · How we verify

NCT04810611

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS

Terminated Phase 1 Last updated 10 October 2025

What this trial tests

Phase 1 trial testing MBG453 in Myelodysplastic Syndromes in 33 participants. Terminated before completion.

Timeline

18 June 2021

Primary endpoint
19 April 2024

19 April 2024

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	18 June 2021
Primary completion	19 April 2024
Estimated completion	19 April 2024
Sites	13 locations across Italy, Israel, South Korea, Australia, Singapore, United States, Spain

Drugs / interventions tested

MBG453 — full drug profile →
NIS793 — full drug profile →
canakinumab (CANAKINUMAB) — full drug profile →

Conditions studied

Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study was to characterize the safety, tolerability and confirm the dose for select single agents and combinations in patients with lower risk (very low, low, and intermediate risk) MDS.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting TGF-β signal transduction for fibrosis and cancer therapy.
Peng D, Fu M, Wang M, Wei Y, et al · · 2022 · cited 752× · PMID 35461253 · DOI 10.1186/s12943-022-01569-x
TGF-β signaling in health, disease, and therapeutics.
Deng Z, Fan T, Xiao C, Tian H, et al · · 2024 · cited 737× · PMID 38514615 · DOI 10.1038/s41392-024-01764-w
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy.
Cai L, Li Y, Tan J, Xu L, et al · · 2023 · cited 232× · PMID 37670328 · DOI 10.1186/s13045-023-01499-1
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y, Zhang H, Liu C, Wang Z, et al · · 2022 · cited 179× · PMID 35978433 · DOI 10.1186/s13045-022-01325-0
TGF-beta signal transduction: biology, function and therapy for diseases.
Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9
TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors.
Sauer N, Janicka N, Szlasa W, Skinderowicz B, et al · · 2023 · cited 89× · PMID 37567938 · DOI 10.1007/s00262-023-03516-1
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Abaza Y, Zeidan AM. · · 2022 · cited 61× · PMID 35883692 · DOI 10.3390/cells11142249
Involvement of inflammasomes in tumor microenvironment and tumor therapies.
Zhang Z, Li X, Wang Y, Wei Y, et al · · 2023 · cited 55× · PMID 36932407 · DOI 10.1186/s13045-023-01407-7

Verify or expand the search:

Other trials of MBG453

Trials testing the same drug.

NCT04878432 — STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS · Phase 2 · terminated
NCT04823624 — MBG453 in Lower Risk MDS · Phase 2 · terminated
NCT04283526 — Study of Select Combinations in Adults With Myelofibrosis · Phase 1 · withdrawn
NCT04150029 — A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy · Phase 2 · terminated
NCT03940352 — HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplast · Phase 1 · terminated

Other recruiting trials for Myelodysplastic Syndromes

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04810611 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 10 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04810611.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing